Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05033288
Other study ID # ROF2181
Secondary ID NCI-2021-08847MC
Status Recruiting
Phase
First received
Last updated
Start date January 20, 2022
Est. completion date August 30, 2028

Study information

Verified date September 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects. There are three types of radiation treatment used for pelvic bone sarcomas: surgery with or without photon/proton therapy, proton therapy alone, and carbon ion therapy alone. The purpose of this study is to compare quality of life among patients treated for pelvic bone sarcomas across the world, and to determine if carbon ion therapy improves quality of life compared to surgery and disease control compared with proton therapy.


Description:

PRIMARY OBJECTIVES: I. Demonstrate whether carbon ion therapy provides improved patient reported health related quality of life (PRO-HRQOL) outcomes and less significant toxicities compared with surgery. II. Demonstrate whether carbon ion therapy provides improved local control versus proton therapy. OUTLINE: Patients complete quality of life questionnaires over 20 minutes at baseline (before any therapy), 2-4 and 5-9 months after completion of therapy, and then annually for up to 5 years. Patients' medical records are also reviewed.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date August 30, 2028
Est. primary completion date August 30, 2027
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: - Males and females >= 15 years of age - Newly diagnosed, histologic confirmation of pelvic chordoma, chondrosarcoma, osteosarcoma, Ewing sarcoma with bone involvement, rhabdomyosarcoma (RMS) with bone involvement or non-RMS soft tissue sarcoma with bone involvement - No evidence of distant sarcoma metastases as determined by clinical examination and any form of imaging - Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2 - Patients capable of childbearing must agree to use adequate contraception - Ability to complete questionnaire(s) by themselves or with assistance - Ability to provide written informed consent - Chemotherapy per institutional guidelines is allowed Exclusion Criteria: - Patients receiving palliative treatment - Recurrent disease - Males and females < 15 years of age - Previous radiation therapy to the site of the sarcoma or area surrounding it such that it would be partially or completely encompassed by the radiation volume needed to treat the current sarcoma. In other words, treatment on this study would require re-irradiation of tissues - Patients with distant sarcoma metastases - Benign pelvic bone histologies - Any of the following: - Pregnant women - Nursing women - Men or women of childbearing potential who are unwilling to employ adequate contraception

Study Design


Intervention

Other:
Electronic Health Record Review
Medical records are reviewed
Quality-of-Life Assessment
Complete quality of life questionnaires

Locations

Country Name City State
United States Mayo Clinic in Florida Jacksonville Florida
United States Mayo Clinic in Rochester Rochester Minnesota
United States Mayo Clinic in Arizona Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average difference in change of functional quality of life (QOL) Will be compared between patients who received carbon ion radiation therapy (CIRT) and surgery utilizing a one-sided test for a two sample t-test for independent means. The Patient Reported Outcomes Measurement Information System (PROMIS)-29 functional score will be calculated and median, mean, and 95% confidence interval will be computed for each arm, with one-sided two-sample t-tests conducted between the surgery +/- radiation therapy (RT) and CIRT arm. Baseline (pre-treatment) to 1 year after completion of treatment
Primary Proportion of patients experiencing local control Will be calculated along with 95% confidence intervals with a one-sided test for non-inferiority to be conducted between the PT and CIRT arms. Up to 5 years after completion of treatment
Primary Progression-free survival - local control The Kaplan-Meier method with likelihood ratio tests will be used to calculate clinical outcomes including local control as well as progression-free survival for each arm and stratified by arm. Up to 5 years after completion of treatment
Primary Progression-free survival - regional control The Kaplan-Meier method with likelihood ratio tests will be used to calculate clinical outcomes including regional control as well as progression-free survival for each arm and stratified by arm. Up to 5 years after completion of treatment
Primary Progression-free survival - distant control The Kaplan-Meier method with likelihood ratio tests will be used to calculate clinical outcomes including distant control as well as progression-free survival for each arm and stratified by arm. Up to 5 years after completion of treatment
Primary Overall survival - local control The Kaplan-Meier method with likelihood ratio tests will be used to calculate clinical outcomes including local control as well as overall survival for each arm and stratified by arm. Up to 5 years after completion of treatment
Primary Overall survival - regional control The Kaplan-Meier method with likelihood ratio tests will be used to calculate clinical outcomes including regional control as well as overall survival for each arm and stratified by arm. Up to 5 years after completion of treatment
Primary Overall survival - distant control The Kaplan-Meier method with likelihood ratio tests will be used to calculate clinical outcomes including distant control as well as overall survival for each arm and stratified by arm. Up to 5 years after completion of treatment
Secondary Secondary and exploratory analyses on toxicity data Secondary and exploratory analyses on data will be conducted utilizing standard logistic regression analysis for acute (< 6 months) and late (> 6 months) toxicity. Up to 5 years after completion of treatment
Secondary Secondary and exploratory analyses on dose volume histogram (DVH) data Secondary and exploratory analyses on data will be conducted utilizing standard logistic regression analysis for acute (< 6 months) and late (> 6 months) toxicity. Up to 5 years after completion of treatment
Secondary Dose volume histogram Secondary and exploratory analyses on toxicity and DVH data will be conducted utilizing standard logistic regression analysis for acute (< 6 months) and late (> 6 months) toxicity. Receiver-operator curves and area-under-the curve will be computed separately for each DVH metric to determine the effect on toxicity, QOL, local control and survival. Up to 5 years after completion of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05039801 - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Phase 1
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitibart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Recruiting NCT04040205 - Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Phase 2
Not yet recruiting NCT06029478 - Understanding Engagement Trends in Chondrosarcoma Clinical Trials
Completed NCT01553539 - Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Phase 2
Completed NCT00004241 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma Phase 1
Active, not recruiting NCT04521686 - Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Phase 1
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Completed NCT02496741 - Metformin And Chloroquine in IDH1/2-mutated Solid Tumors Phase 1/Phase 2
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Terminated NCT00543712 - A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) Phase 2
Recruiting NCT05861245 - Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base N/A
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Recruiting NCT04278781 - AG-120 in People With IDH1 Mutant Chondrosarcoma Phase 2
Recruiting NCT04055220 - Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas N/A
Recruiting NCT04673942 - A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors Phase 2
Completed NCT01609179 - IPI-926 Extension Protocol for Continuation of Treatment With IPI-926 N/A
Completed NCT01560260 - Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors Phase 2
Completed NCT02073994 - Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation Phase 1

External Links